Big pharma has an interest in rich people being sick
What profit is
there in a healthy population? If everyone were healthy, it would be the job of
the pharmaceutical companies to persuade us that we were not well
Giles Fraser
The Guardian, Friday 17 October 2014 / http://www.theguardian.com/commentisfree/belief/2014/oct/17/big-pharma-interest-rich-people-sick?CMP=fb_gu
The giant pharmaceutical company
GlaxoSmithKline said yesterday that its work on a vaccine for Ebola will “come
too late” to do anything about the current situation. Even now it is trying to
compress trials that would normally take a decade into a year. The impression
it gives is that it is working flat out, no holds barred. But hang on a moment.
Ebola was discovered back in 1976. What has GlaxoSmithKline been doing since
then? Answer: not much.
A small clue to why can be found by looking
at the stock price of Tekmira Pharmaceuticals, the Canadian-based drugs firm
that some investors seem to think is leading the pack on Ebola research.
Tekmira shares rose a massive 180% from mid-July to October, with most of the
share-price action coming when the virus jumped to Europe and the US .
Ebola has been killing people in central
and western Africa for at least 38 years – but
it’s only when the virus becomes a threat to the developed world that there is
seen to be a profit in it. I know it sounds cynical to say it flat out like
that – but it sounds cynical because it is. What business case is there for
developing drugs to save the lives of poor Africans when they don’t have the
money to pay for them? Especially when there is so much more profit to be had
in – for instance – giving rich white men erections. As a study in last year’s
Lancet showed, of the 336 new drugs developed in the first decade of this
century, only four of them were for what are known in jargon as neglected
tropical diseases – three for malaria and one for diarrhoea.
The point being this: the business model of
market-driven big (or even medium-sized) pharma does not work well to address
the challenges posed by a virus that ultimately has no respect for geography or
bank balance. Some of the developed world’s early interest in Ebola was in
whether it could be weaponised. It was said that the Russian biological weapons
unit – Biopreparat – had turned Ebola into an aerosol spray.
All of which is red meat for conspiracy
theorists (like those who tell you that the patent for the Ebola virus is owned
by the US
government, which is true). But my suspicion is not about shady government
actions but about basic capitalist economics. Isn’t it interesting that there
is money about to ask scientists to turn a virus into a weapon, but not the
money about to ask scientists to find a vaccine? And by the time there’s a
market for a vaccine, it’s too late.
What better example of what is commonly
called market failure – that state of affairs in which market forces do not
make for desirable outcomes. Here’s another example: remember Nelson Mandela
having to take on the big pharmaceutical companies as thousands of dying South
Africans were unable to afford Aids drugs. Apparently, the market-driven
economics of health care do not have an answer to a virus that begins in a part
of the world where there isn’t much money. And that is often where dangerous
viruses begin. Which is precisely why market forces will not be able to save
us.
Indeed, on the contrary, market-driven
healthcare is incentivised to keep us sick. For what profit is there in a
healthy population? If everyone were healthy, it would be the job of the
pharmaceutical companies to persuade us that we were not well, that certain
things about us needed fixing, putting right (even if they didn’t).
Its a bit like Friedrich Nietzsche’s
criticism of the Christian priest: that the priest first has to poison us into
imagining we are unwell – and thus in need of saving – before he can present
himself as the cure, as salvation. There is no market for salvation in a
sinless world. Of course, big pharma presents itself as evidence-based and
scientific. Not at all like Nietzsche’s Christianity. But it’s not the science
that calls the tune. It is the stock price. And the stock price goes up when
rich people feel threatened.
Sem comentários:
Enviar um comentário